Abstract:GPR84 is a poorly characterized, nominally orphan, proinflammatory G protein-coupled receptor that can be activated by medium chain length fatty acids. It is attracting considerable interest as a potential therapeutic target for antagonist ligands in both inflammatory bowel diseases and idiopathic pulmonary fibrosis. Successful screening of more than 300 000 compounds from a small molecule library followed by detailed analysis of some 50 drug-like hits identified 3-((5,6-bis(4-methoxyphenyl)-1,2,4-triazin-3-yl)methyl)-1H-indole as a high affinity and highly selective competitive antagonist of human GPR84. Tritiation of a di-iodinated form of the core structure produced [3H]3-((5,6-diphenyl-1,2,4-triazin-3-yl)methyl)-1H-indole, which allowed effective measurement of receptor levels in both transfected cell lines and lipopolysaccharide-treated THP-1 monocyte/macrophage cells. Although this compound series lacks significant affinity at mouse GPR84, homology modeling and molecular dynamics simulations provided a potential rationale for this difference, and alteration of two residues in mouse GPR84 to the equivalent amino acids in the human orthologue, predicted to open the antagonist binding pocket, validated this model. Sequence alignment of other species orthologues further predicted binding of the compounds as high affinity antagonists at macaque, pig, and dog GPR84 but not at the rat orthologue, and pharmacological experiments confirmed these predictions. These studies provide a new class of GPR84 antagonists that display species selectivity defined via receptor modeling and mutagenesis.This article has not yet been cited by other publications.

Discovery of a First-in-Class GPR183 Antagonist for the Potential Treatment of Rheumatoid Arthritis

Discovery of a Highly Potent Oxysterol Receptor GPR183 Antagonist Bearing the Benzo[ d ]thiazole Structural Motif for the Treatment of Inflammatory Bowel Disease (IBD)

Discovery and Characterization of Novel Antagonists of the Proinflammatory Orphan Receptor GPR84

Discovery of Anthranilic Acid Derivatives as Antagonists of the Pro-Inflammatory Orphan G Protein-Coupled Receptor GPR17

Discovery of a novel GPR35 agonist with high and equipotent species potency for oral treatment of IBD

Small Molecule Inhibits Activity of Scavenger Receptor A: Lead Identification and Preliminary Studies

Discovery of a potent, Highly selective, and In vivo anti-inflammatory Efficacious, P2Y 6 R antagonist with a novel quinoline-pyrazole scaffold

Unsymmetrical Phosphodiesters as GPR84 Antagonists with High Blood Exposure for the Treatment of Lung Inflammation

Sphingosine-1-phosphate: a Potential Therapeutic Target for Rheumatoid Arthritis

Phosphodiesters as GPR84 Antagonists for the Treatment of Ulcerative Colitis

Discovery of the Clinical Candidate IDOR-1117-2520: A Potent and Selective Antagonist of CCR6 for Autoimmune Diseases

Discovery of Novel and Selective GPR17 Antagonists as Pharmacological Tools for Developing New Therapeutic Strategies in Diabetes and Obesity

“Relative Symmetry with Electronegativity of Different Key-Groups” Strategy for MRGPRX2 Antagonist Design and Its Effect on Antigen-Induced Pulmonary Inflammation

Design, synthesis, and characterization of rhein analogs as novel inhibitors of scavenger receptor A

Discovery of novel triazine derivatives as potent retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonists

Discovery of a Potent and Selective CCR8 Small Molecular Antagonist IPG7236 for the Treatment of Cancer

Preclinical development of GR1501, a human monoclonal antibody that neutralizes interleukin-17A

Discovery and Optimization of N -Acyl-6-sulfonamide-tetrahydroquinoline Derivatives as Novel Non-Steroidal Selective Glucocorticoid Receptor Modulators

Discovery of a novel nonsteroidal selective glucocorticoid receptor modulator by virtual screening and bioassays

Discovery and pharmacological effects of a novel GPR142 antagonist

Discovery of TRPA1 Antagonist GDC-6599: Derisking Preclinical Toxicity and Aldehyde Oxidase Metabolism with a Potential First-in-Class Therapy for Respiratory Disease